Skip to main content

Table 3 Characteristics of the Barcelona patients and controls

From: Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer’s disease, but not in cerebral amyloid angiopathy

  aMCI
n = 33
AD
n = 17
Controls
n = 50
p-value
Age (years) 70 ± 3 67 ± 7 63 ± 4 p < 0.0001a
Sex, M/F (n) 10/23 8/9 25/25 p = 0.20b
MMSE score 26 [25–28] 20 [19–25] 29 [29–30] p < 0.000d
APOE genotype ε4+: n = 24
ε4−: n = 8
N.A.: n = 1
ε4+: n = 6
ε4−: n = 10
N.A.: n = 1
ε4+: n = 10
ε4−: n = 38
N.A.: n = 2
p < 0.0001c
TP (mg/ml) 0.78 [0.72–0.88] 0.79 [0.71–0.88] 0.78 [0.69–1.04] p = 0.99d
T-tau (pg/ml) 647 [411–823] n = 15; 742 [598–1163] 265.0 [227–305] p < 0.0001d
P-tau (pg/ml) 101.3 [78.0–143.8] 114.1 [79.9–147.6] 40.0 [29.3–47.8] p < 0.0001d
Aβ42 (pg/ml) 511 [421–623] 420 [372–575] 1240 [1036–1600] p < 0.0001d
NLK (ng/ml) 3.88 [3.00–5.24] 4.17 [3.61–4.60] 2.82 [2.30–3.60] p < 0.0001d
YKL-40 (ng/ml) n = 13; 324 ± 63 n = 5; 323 ± 40 n = 29; 226 ± 51 p < 0.0001a
  1. Characteristics of the Barcelona AD-control group. Medians and [IQR] are reported, except for age and YKL-40 (mean ± SD), and sex (n). TP, T-tau, P-tau, Aβ42, NLK and YKL-40 were measured in CSF
  2. Abbreviations: AD Alzheimer’s disease, Aβ42 amyloid beta-42, APOE Apolipoprotein E, aMCI amnestic mild cognitive impairment, F female, IQR interquartile range, M male, MMSE Mini-Mental State Examination, N.A. not available, NLK neuroleukin, P-tau phosphorylated tau, SD standard deviation, TP total protein, T-tau total tau, YKL-40 protein associated with neuro-inflammation and Alzheimer’s disease, named after the first three N-terminal amino acids: tyrosine (Y), lysine (K), and leucine (L) and its molecule mass (40 kDa), also known as chitinase-3 like-protein 1
  3. aANOVA
  4. bChi-square test
  5. cFisher’s exact test
  6. dKruskal-Wallis test